High-throughput simultaneous determination of the HIV protease inhibitors indinavir and L-756423 in human plasma using semi-automated 96-well solid phase extraction and LC-MS/MS.
A method for the simultaneous determination of the HIV protease inhibitors indinavir and L-756423, in human plasma has been developed. Plasma samples (0.5 ml) were extracted using a 3M Empore 96-well plate in the mixed phase cation exchange (MPC) format. The extraction method was automated through the application of both the Packard 204DT and TOMTEC Quadra 96 work stations, and the resulting extracts were analyzed using a PE-Sciex API-3000 LC-MS/MS with a heated nebulizer interface (500 degrees C). The assay was linear in the concentration range 1-2500 ng/ml for indinavir and 5 2500 ng/ml for L-756423 when 0.5-ml aliquots of plasma were extracted. Recoveries of indinavir and L-756423 were greater than 76 and 80%, respectively, over the calibration curve range when using the described sample preparation method. Within-batch precision and accuracy for the quantitation of indinavir over the range 1-2500 ng/ml were 5.4% R.S.D. or less and within 4.0%, respectively. Within-batch precision and accuracy for the quantitation of L-756423 over the range 5-2500 ng/ml were 5.3% R.S.D. or less and within 3.4%, respectively. Interbatch variability for the analysis of indinavir QC samples at low (3 ng/ml), middle (250 ng/ml) and high (2250 ng/ml) were 3.2, 2.9, and 1.9%, respectively. Interbatch variability for the analysis of L-756423 QC samples at low (15 ng/ml), middle (250 ng/ml) and high (2250 ng/ml) concentration were 2.0, 2.5, and 3.3%, respectively. The validated assay was used in support of human clinical trials.
Rose
M J
MJ
Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA. mark_rose@merck.com
Merschman
S A
SA
Eisenhandler
R
R
Woolf
E J
EJ
Yeh
K C
KC
Lin
L
L
Fang
W
W
Hsieh
J
J
Braun
M P
MP
Gatto
G J
GJ
Matuszewski
B K
BK
D019380:Anti-HIV Agents / Q000097:blood* / Q000493:pharmacokinetics; D001331:Automation; D002853:Chromatography, Liquid / Q000379:methods*; D017320:HIV Protease Inhibitors / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D007189:Indans / Q000097:blood* / Q000493:pharmacokinetics; D019469:Indinavir / Q000097:blood* / Q000493:pharmacokinetics; D013058:Mass Spectrometry / Q000379:methods*; D010879:Piperazines / Q000097:blood* / Q000493:pharmacokinetics; D012015:Reference Standards; D015203:Reproducibility of Results
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D007189:Indans; D010879:Piperazines; D019469:Indinavir; C122089:L 756423